Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.56
+0.02 (+3.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $35.1M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$114M
P/E
N/A
•EV/EBITDA
11.0x
↓ROE
249.1%
↑Gross Margin
33.9%
↓Debt/Equity
-13.27
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.2%
FCF CAGR
—
FCF margin
0.0%
FCF / Net income
-0.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $500.6M · net income $-118.2M · FCF $94000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $500.6M | $500.6M | $561.6M | $518.6M | $405.9M |
| Net Income | $-118.2M | $-118.2M | $-85.0M | $-48.2M | $-80.9M |
| EBITDA | $59.9M | $59.9M | $68.1M | $82.3M | $29.3M |
| EPS | -0.58 | -0.58 | -0.40 | -0.24 | -0.44 |
| Gross Margin | 33.9% | 33.9% | 32.8% | 29.9% | 33.1% |
| Operating Margin | -0.2% | -0.2% | 0.8% | -0.7% | -0.5% |
| Net Margin | -23.6% | -23.6% | -15.1% | -9.3% | -19.9% |
| Balance Sheet | |||||
| Debt/Equity | -13.27 | -13.27 | 8.19 | 4.01 | 3.45 |
| Current Ratio | 1.92 | 1.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $94000.00 | $94000.00 | $38.1M | $35.1M | $-164.3M |
| Returns | |||||
| ROE | 249.1% | 249.1% | -119.7% | -33.7% | -49.5% |
| Valuation | |||||
| EV/EBITDA | 10.97 | 10.97 | 8.64 | 8.90 | 25.96 |
| P/B | — | — | 1.35 | 1.62 | 1.66 |
| Growth & Yield | |||||
| Revenue Growth | -10.9% | -10.9% | 8.3% | 27.8% | — |
| EPS Growth | -45.0% | -45.0% | -66.7% | 45.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+64.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.40 → -0.58
Residual
+64.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.